Next Article in Journal
Fabrication of 3D Capillary Vessel Models with Circulatory Connection Ports
Next Article in Special Issue
Deterministic Capture of Individual Circulating Tumor Cells Using a Flow-Restricted Microfluidic Trap Array
Previous Article in Journal
Editorial for the Special Issue on MEMS Mirrors
Previous Article in Special Issue
The Viability of Single Cancer Cells after Exposure to Hydrodynamic Shear Stresses in a Spiral Microchannel: A Canine Cutaneous Mast Cell Tumor Model
Open AccessFeature PaperReview

Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)

by 1,†, 1,2,†, 1, 3 and 1,2,*
1
Department of Biomedical Engineering, School of Life Sciences, Ulsan National Institute of Science and Technology (UNIST), UNIST-gil 50, Ulsan 44919, Korea
2
Center for Soft and Living Matter, Institute for Basic Science (IBS), UNIST-gil 50, Ulsan 44919, Korea
3
Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, 179, Gudeok-ro, Seo-Gu, Busan 49241, Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Micromachines 2018, 9(3), 100; https://doi.org/10.3390/mi9030100
Received: 1 February 2018 / Revised: 18 February 2018 / Accepted: 26 February 2018 / Published: 28 February 2018
(This article belongs to the Special Issue Microfluidics for Circulating Biomarkers)
Lung cancer is by far the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. Recent advances in the understanding of the biology of tumors and in highly sensitive detection technologies for molecular analysis offer targeted therapies, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. However, our understanding of an individual patient’s lung cancer is often limited by tumor accessibility because of the high risk and invasive nature of current tissue biopsy procedures. “Liquid biopsy”, the analysis of circulating biomarkers from peripheral blood, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), offers a new source of cancer-derived materials that may reflect the status of the disease better and thereby contribute to more personalized treatment. In this review, we examined the clinical significance and uniqueness of CTCs and ctDNA from NSCLC patients, isolation and detection methods developed to analyze each type of circulating biomarker, and examples of clinical studies of potential applications for early diagnosis, prognosis, treatment monitoring, and prediction of resistance to therapy. We also discuss challenges that remain to be addressed before such tools are implemented for routine use in clinical settings. View Full-Text
Keywords: liquid biopsy; circulating biomarkers; circulating tumor cells; circulating tumor DNA; non-small cell lung cancer liquid biopsy; circulating biomarkers; circulating tumor cells; circulating tumor DNA; non-small cell lung cancer
Show Figures

Figure 1

MDPI and ACS Style

Lim, M.; Kim, C.-J.; Sunkara, V.; Kim, M.-H.; Cho, Y.-K. Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA). Micromachines 2018, 9, 100. https://doi.org/10.3390/mi9030100

AMA Style

Lim M, Kim C-J, Sunkara V, Kim M-H, Cho Y-K. Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA). Micromachines. 2018; 9(3):100. https://doi.org/10.3390/mi9030100

Chicago/Turabian Style

Lim, Minji; Kim, Chi-Ju; Sunkara, Vijaya; Kim, Mi-Hyun; Cho, Yoon-Kyoung. 2018. "Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)" Micromachines 9, no. 3: 100. https://doi.org/10.3390/mi9030100

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop